Cepheid is expanding its Oncology portfolio to deliver life-changing technology to physicians and their cancer patients globally. We also offer a rapid test that detects the genetic risk for thrombosis.
Xpert® BCR-ABL Ultra
Sensitive and quantitative monitoring of BCR-ABL mRNA in patients with chronic myelogenous leukemia (CML)
Xpert® Breast Cancer STRAT4
Standardized breast cancer ESR1/PGR/ERBB2/MKi67 mRNA biomarker assessment in less than two hours
Xpert® FII & FV
30-minute Test for Genetic Risk of Thrombosis